269 Followers on Owler

Amplyx

Read more
Ciara Kennedy's photo - President & CEO of Amplyx

President & CEO

Ciara Kennedy

CEO Approval Rating

89/100

Founded:

2006

Status:

Est. Annual Revenue
$10M
Agree?
Est. Employees
40
Agree?

AMPLYX TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Amplyx's company profile
Ciara Kennedy's photo - President & CEO of Amplyx

Ciara Kennedy

President & CEO

89/100
40
$170.7M
$10M
View Profile
1
Amplyx's Competitor - Cidara logo
Jeffrey Stein's photo - President & CEO of Cidara

Jeffrey Stein

President & CEO

89/100
68
$251.3M
$46.1M
View Profile
2
Amplyx's Competitor - Seres Therapeutics logo
Eric D. Shaff's photo - President & CEO of Seres Therapeutics

Eric D. Shaff

President & CEO

89/100
145
$267.9M
$155.3M
View Profile
3
Amplyx's Competitor - Scynexis logo
Marco Taglietti's photo - President & CEO of Scynexis

Marco Taglietti

President & CEO

88/100
24
$108.4M
$12.6M
View Profile
4
Amplyx's Competitor - Visterra logo
Brian J. G. Pereira's photo - President & CEO of Visterra

Brian J. G. Pereira

President & CEO

90/100
90
$144.5M
$4.5M
View Profile
5
Amplyx's Competitor - Viamet Pharma logo
Robert Schotzinger's photo - President & CEO of Viamet Pharma

Robert Schotzinger

President & CEO

71/100
100
$172.8M
$6M
View Profile
6
Amplyx's Competitor - Gossamer Bio logo
Faheem Hasnain's photo - President & CEO of Gossamer Bio

Faheem Hasnain

President & CEO

90/100
118
$594.5M
View Profile
7
Amplyx's Competitor - Basilea logo
David Veitch's photo - CEO of Basilea

David Veitch

CEO

86/100
225
- -
$138.4M
View Profile
8
Amplyx's Competitor - Iconic Therapeutics logo
William L. Greene's photo - CEO of Iconic Therapeutics

William L. Greene

CEO

77/100
40
$135.7M
$12M
View Profile
9
Amplyx's Competitor - Entasis logo
Manos Perros's photo - President & CEO of Entasis

Manos Perros

President & CEO

88/100
33
$262M
$7M
View Profile
10
Amplyx's Competitor - NGM Bio logo
David J. Woodhouse's photo - CEO of NGM Bio

David J. Woodhouse

CEO

89/100
210
$344.8M
$76.7M
View Profile
11
Amplyx's Competitor - AiCuris logo
Holger Zimmermann's photo - CEO of AiCuris

Holger Zimmermann

CEO

87/100
70
$75M
$12.1M
View Profile
12
Amplyx's Competitor - Xellia logo
Carl Ake Carlsson's photo - President & CEO of Xellia

Carl Ake Carlsson

President & CEO

81/100
1,500
- -
$291.4M
View Profile

Missing a competitor? Contribute!

Cidara is perceived as one of Amplyx's biggest rivals. Cidara is headquartered in San Diego, California, and was founded in 2012. Like Amplyx, Cidara also operates in the Biotechnology industry. Cidara generates 460% the revenue of Amplyx.

Seres Therapeutics is one of Amplyx's top competitors. Seres Therapeutics is a Public company that was founded in 2010 in Cambridge, Massachusetts. Like Amplyx, Seres Therapeutics also operates in the Biotechnology field. Compared to Amplyx, Seres Therapeutics has 115 more employees.

Scynexis has been one of Amplyx's top competitors. Scynexis was founded in 2000 in Jersey City, New Jersey. Like Amplyx, Scynexis also works within the Biotechnology field. Scynexis generates $2.7M more revenue than Amplyx.

Amplyx Acquisitions

No recent acquisitions found related to Amplyx

Amplyx Funding History

Since Amplyx was founded in 2006, it has participated in 5 rounds of funding. In total Amplyx has raised $170.7M. Amplyx's last funding round was on May 2020 for a total of $53.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series C
May 2020
$53M
Series C
Jul 2017
$67M
Series B
Feb 2016
$8.7M
Series B
Oct 2015
$40.5M
Debt
Aug 2015
$1.5M
-

Since Amplyx was founded in 2006, it has participated in 5 rounds of funding. In total Amplyx has raised $170.7M. Amplyx's last funding round was on May 2020 for a total of $53.0M

Amplyx Investments

No recent investments found related to Amplyx

Amplyx News

June 12, 2020Xconomy

Amplyx Pharmaceuticals added Chris LeMasters as chief operating officer

Amplyx Pharmaceuticals added Chris LeMasters as chief operating officer... See more »
May 18, 2020St Louis Post Dispatch

San Diego biotech raises $90 million to treat infections in people with weak immune systems

SAN DIEGO - San Diego biotech company Amplyx Pharmaceuticals announced Tuesday that it has completed ... See more »
September 22, 2019San Diego Business Journal

Amplx Adds to Pipeline, Unveils Clinical Trial Data

Amplx Pharmaceuticals recently revealed promising data for a drug designed to treat life-threatening ... See more »
September 17, 2019Xconomy

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Pharmaceuticals, which is testing a new type of drug against life-threatening infections acqui... See more »
September 17, 2019MarketScreener

Amplyx unveils expanded pipeline and reports Phase 2 data from lead programme

(marketscreener.com) Amplyx unveils expanded pipeline and reports Phase 2 data from lead programme 17... See more »
September 16, 2019The Pharma Letter

BRIEF-Amplyx in-licenses Ph II candidate from Novartis

US biotech firm Amplyx Pharmaceuticals has executed an exclusive worldwide license agreement with Swi... See more »
April 15, 2019Xconomy

As Drug Resistance Grows, Amplyx Tests New Antifungal Drug

While fungal infections may seem like an annoyance rather than a serious health problem, sick people ... See more »

Amplyx Press Releases

April 12, 2019StreetInsider

Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections,... See more »
October 10, 2017GlobeNewswire

Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections

Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment o... See more »
September 22, 2017StreetInsider

Amplyx Pharmaceuticals Announces Presentations at IDWeek 2017

Amplyx Pharmaceuticals, a biotechnology company developing novel antimicrobial agents for life-threat... See more »
September 25, 2016Press Release Rocket

Latest Pipeline Review H2 2016 with Detail Drugs Profile

Chemotherapy Introduced Peripheral Neuropathy Pipeline Review H2 2016 'Chemotherapy Induced Periphera... See more »
September 9, 2016Business Wire

Amplyx Pharma, Bakker Medical, Biosergen - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Candidiasis - Pipeli... See more »
August 9, 2016NewsMaker

HIV / AIDS Treatment Pipeline Market Review H1 2016

MarketStudyReport.com adds "HIV / AIDS - Pipeline Review, H1 2016" new report to its research databas... See more »

Social Media

Amplyx Headquarters

12730 High Bluff Drive Suite 160

San Diego, California92130

858-345-1755

Driving Directions »

Trending Companies

Amplyx Summary

ABOUT

Overview

Amplyx is a California-based biotechnology company that researches, develops and commercializes novel therapies to treat patients with fungal infections. Amplyx was founded in 2006. Amplyx's headquarters is located in San Diego, California, USA 92130....

CEO

Amplyx's President & CEO, Ciara Kennedy, currently has an approval rating of 89%. Amplyx's primary competitors are Cidara, Seres Therapeutics & Scynexis.

Website

amplyx.com

Frequently Asked Questions about Amplyx

  1. When was Amplyx founded?

    Amplyx was founded in 2006
  2. Who is Amplyx's CEO?

    Amplyx's CEO is Ciara Kennedy
  3. How much revenue does Amplyx generate?

    Amplyx generates $10M in revenue
  4. How much funding does Amplyx have?

    Amplyx has historically raised $170.7M in funding
  1. Where is Amplyx's headquarters?

    Amplyx's headquarters is in San Diego California, USA
  2. How many employees does Amplyx have?

    Amplyx has 40 employees
  3. What sector does Amplyx operate in?

    Amplyx is in Biotechnology
  4. Who are Amplyx's competitors?

    Amplyx's top competitors are Cidara, Seres Therapeutics, Scynexis